Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Neckers Website

Leonard M. Neckers, Ph.D.

Selected Publications
1)  Tsutsumi S, Scroggins B, Koga F, Lee MJ, Trepel J, Felts S, Carreras C, Neckers L.
A small molecule cell-impermeant Hsp90 antagonist inhibits tumor cell motility and invasion.
Oncogene. 27: 2478-87, 2008. [Journal]
2)  Asami Y, Kakeya H, Komi Y, Kojima S, Nishikawa K, Beebe K, Neckers L, Osada H.
Azaspirene, a fungal product, inhibits angiogenesis by blocking Raf-1 activation.
Cancer Sci. 2008. [Journal]
3)  Barluenga S, Wang C, Fontaine JG, Aouadi K, Beebe K, Tsutsumi S, Neckers L, Winssinger N.
Divergent synthesis of a pochonin library targeting HSP90 and in vivo efficacy of an identified inhibitor.
Angew. Chem. Int. Ed. Engl. 47: 4432-5, 2008. [Journal]
4)  Gallegos Ruiz MI, Floor K, Roepman P, Rodriguez JA, Meijer GA, Mooi WJ, Jassem E, Niklinski J, Muley T, van Zandwijk N, Smit EF, Beebe K, Neckers L, Ylstra B, Giaccone G.
Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target.
PLoS ONE. 3: e0001722, 2008. [Journal]
5)  Kajiguchi T, Lee S, Lee MJ, Trepel JB, Neckers L.
KIT regulates tyrosine phosphorylation and nuclear localization of beta-catenin in mast cell leukemia.
Leuk. Res. 32: 761-70, 2008. [Journal]
6)  Park Y, Kubo A, Komiya T, Coxon A, Beebe K, Neckers L, Meltzer PS, Kaye FJ.
Low-penetrant RB allele in small-cell cancer shows geldanamycin instability and discordant expression with mutant ras.
Cell Cycle. 7, 2008. [Journal]
7)  Pashtan I, Tsutsumi S, Wang S, Xu W, Neckers L.
Targeting Hsp90 prevents escape of breast cancer cells from tyrosine kinase inhibition.
Cell Cycle. 7: 2936-41, 2008. [Journal]
8)  Lev A, Takeda K, Zanker D, Maynard JC, Dimberu P, Waffarn E, Gibbs J, Netzer N, Princiotta MF, Neckers L, Picard D, Nicchitta CV, Chen W, Reiter Y, Bennink JR, Yewdell JW.
The exception that reinforces the rule: crosspriming by cytosolic peptides that escape degradation.
Immunity. 28: 787-98, 2008. [Journal]
9)  Ansar S, Burlison JA, Hadden MK, Yu XM, Desino KE, Bean J, Neckers L, Audus KL, Michaelis ML, Blagg BS.
A non-toxic Hsp90 inhibitor protects neurons from Abeta-induced toxicity.
Bioorg. Med. Chem. Lett. 17: 1984-90, 2007. [Journal]
10)  Scroggins BT, Robzyk K, Wang D, Marcu MG, Tsutsumi S, Beebe K, Cotter RJ, Felts S, Toft D, Karnitz L, Rosen N, Neckers L.
An acetylation site in the middle domain of Hsp90 regulates chaperone function.
Mol. Cell. 25: 151-9, 2007. [Journal]
11)  Jung Y, Xu W, Kim H, Ha N, Neckers L.
Curcumin-induced degradation of ErbB2: A role for the E3 ubiquitin ligase CHIP and the Michael reaction acceptor activity of curcumin.
Biochim. Biophys. Acta. 1773: 383-90, 2007. [Journal]
12)  Workman P, Burrows F, Neckers L, Rosen N.
Drugging the cancer chaperone HSP90: Combinatorial therapeutic exploitation of oncogene addiction and tumor stress.
Ann N Y Acad Sci. 2007. [Journal]
13)  Tsutsumi S, Neckers L.
Extracellular heat shock protein 90: A role for a molecular chaperone in cell motility and cancer metastasis.
Cancer Sci. 98: 1536-9, 2007. [Journal]
14)  Kajiguchi T, Chung EJ, Lee S, Stine A, Kiyoi H, Naoe T, Levis MJ, Neckers L, Trepel JB.
FLT3 regulates beta-catenin tyrosine phosphorylation, nuclear localization, and transcriptional activity in acute myeloid leukemia cells.
Leukemia. 2007. [Journal]
15)  Neckers L.
Heat shock protein 90: the cancer chaperone.
J. Biosci. 32: 517-30, 2007. [Journal]
16)  Sudarshan S, Linehan WM, Neckers L.
HIF and fumarate hydratase in renal cancer.
Br. J. Cancer. 96: 403-7, 2007. [Journal]
17)  Neckers L, Kern A, Tsutsumi S.
Hsp90 inhibitors disrupt mitochondrial homeostasis in cancer cells.
Chem. Biol. 14: 1204-6, 2007. [Journal]
18)  Linehan WM, Pinto PA, Srinivasan R, Merino M, Choyke P, Choyke L, Coleman J, Toro J, Glenn G, Vocke C, Zbar B, Schmidt LS, Bottaro D, Neckers L.
Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics.
Clin. Cancer Res. 13: 671s-679s, 2007. [Journal]
19)  Williams CR, Tabios R, Linehan WM, Neckers L.
Intratumor Injection of the Hsp90 Inhibitor 17AAG Decreases Tumor Growth and Induces Apoptosis in a Prostate Cancer Xenograft Model.
J. Urol. 178: 1528-32, 2007. [Journal]
20)  Xu W, Yuan X, Beebe K, Xiang Z, Neckers L.
Loss of Hsp90 association up-regulates Src-dependent ErbB2 activity.
Mol. Cell. Biol. 27: 220-8, 2007. [Journal]
21)  Koga F, Tsutsumi S, Neckers LM.
Low dose geldanamycin inhibits hepatocyte growth factor and hypoxia-stimulated invasion of cancer cells.
Cell Cycle. 6: 1393-402, 2007. [Journal]
22)  Sudarshan S, Pinto PA, Neckers L, Linehan WM.
Mechanisms of disease: hereditary leiomyomatosis and renal cell cancer--a distinct form of hereditary kidney cancer.
Nature clinical practice. Urology. 4: 104-10, 2007. [Journal]
23)  Bratslavsky G, Sudarshan S, Neckers L, Linehan WM.
Pseudohypoxic pathways in renal cell carcinoma.
Clin. Cancer Res. 13: 4667-71, 2007. [Journal]
24)  Xu W, Soga S, Beebe K, Lee MJ, Kim YS, Trepel J, Neckers L.
Sensitivity of epidermal growth factor receptor and ErbB2 exon 20 insertion mutants to Hsp90 inhibition.
Br. J. Cancer. 97: 741-4, 2007. [Journal]
25)  Xu W, Neckers L.
Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells.
Clin. Cancer Res. 13: 1625-9, 2007. [Journal]
26)  Kim H, Jeon H, Kong H, Yang Y, Choi B, Kim YM, Neckers L, Jung Y.
A molecular mechanism for the anti-inflammatory effect of taurine-conjugated 5-aminosalicylic acid in inflamed colon.
Mol. Pharmacol. 69: 1405-12, 2006. [Journal]
27)  Neckers L.
Chaperoning oncogenes: Hsp90 as a target of geldanamycin.
Handbook of experimental pharmacology. 259-77, 2006. [Journal]
28)  Marcu MG, Jung YJ, Lee S, Chung EJ, Lee MJ, Trepel J, Neckers L.
Curcumin is an inhibitor of p300 histone acetylatransferase.
Medicinal chemistry (Sh?ariqah, United Arab Emirates). 2: 169-74, 2006. [Journal]
29)  Mimnaugh EG, Xu W, Vos M, Yuan X, Neckers L.
Endoplasmic reticulum vacuolization and valosin-containing protein relocalization result from simultaneous hsp90 inhibition by geldanamycin and proteasome inhibition by velcade.
Mol. Cancer Res. 4: 667-81, 2006. [Journal]
30)  Koga F, Xu W, Karpova TS, McNally JG, Baron R, Neckers L.
Hsp90 inhibition transiently activates Src kinase and promotes Src-dependent Akt and Erk activation.
Proc. Natl. Acad. Sci. U.S.A. 103: 11318-22, 2006. [Journal]
31)  Lattouf JB, Srinivasan R, Pinto PA, Linehan WM, Neckers L.
Mechanisms of disease: the role of heat-shock protein 90 in genitourinary malignancy.
Nature clinical practice. Urology. 3: 590-601, 2006. [Journal]
32)  Burlison JA, Neckers L, Smith AB, Maxwell A, Blagg BS.
Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of hsp90.
J. Am. Chem. Soc. 128: 15529-36, 2006. [Journal]
33)  Chiosis G, Neckers L.
Tumor selectivity of Hsp90 inhibitors: the explanation remains elusive.
ACS Chem. Biol. 1: 279-84, 2006. [Journal]
34)  Yang Q, Kim YS, Lin Y, Lewis J, Neckers L, Liu ZG.
Tumour necrosis factor receptor 1 mediates endoplasmic reticulum stress-induced activation of the MAP kinase JNK.
EMBO Rep. 7: 622-7, 2006. [Journal]
35)  Neckers L.
Using natural product inhibitors to validate hsp90 as a molecular target in cancer.
Current topics in medicinal chemistry. 6: 1163-71, 2006. [Journal]
36)  Yu XM, Shen G, Neckers L, Blake H, Holzbeierlein J, Cronk B, Blagg BS.
Hsp90 inhibitors identified from a library of novobiocin analogues.
J. Am. Chem. Soc. 127: 12778-9, 2005. [Journal]
37)  Kim H, Kong H, Choi B, Yang Y, Kim Y, Lim MJ, Neckers L, Jung Y.
Metabolic and pharmacological properties of rutin, a dietary quercetin glycoside, for treatment of inflammatory bowel disease.
Pharm. Res. 22: 1499-509, 2005. [Journal]
38)  Wang D, Xu W, McGrath SC, Patterson C, Neckers L, Cotter RJ.
Direct identification of ubiquitination sites on ubiquitin-conjugated CHIP using MALDI mass spectrometry.
J. Proteome Res. 4: 1554-60, , ,. [Journal]
39)  Neckers L, Blagg B, Han H, Yu X, inventor; DHHS, assignee.
Novobiocin Analogues As Anticancer Agents.
Patent Pending, Filed in 2005. Application No. 11/266,149. Pending [Patent]
40)  Gotlib J, Berubé C, Growney JD, Chen CC, George TI, Williams C, Kajiguchi T, Ruan J, Lilleberg SL, Durocher JA, Lichy JH, Wang Y, Cohen PS, Arber DA, Heinrich MC, Neckers L, Galli SJ, Gilliland DG, Coutré SE.
Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation.
Blood. 2005. [Journal]
41)  Isaacs JS, Jung YJ, Mole DR, Lee S, Torres-Cabala C, Chung YL, Merino M, Trepel J, Zbar B, Toro J, Ratcliffe PJ, Linehan WM, Neckers L.
HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: Novel role of fumarate in regulation of HIF stability.
Cancer Cell. 8: 143-53, 2005. [Journal]
42)  Mimnaugh EG, Neckers LM.
Measuring ubiquitin conjugation in cells.
Methods Mol. Biol. 301: 223-41, 2005. [Journal]
43)  Wei MH, Toure O, Glenn GM, Pithukpakorn M, Neckers L, Stolle C, Choyke P, Grubb R, Middelton L, Turner ML, Walther MM, Merino MJ, Zbar B, Linehan WM, Toro JR.
Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer.
J Med Genet. 2005. [Journal]
44)  Grem JL, Morrison G, Guo XD, Agnew E, Takimoto CH, Thomas R, Szabo E, Grochow L, Grollman F, Hamilton JM, Neckers L, Wilson RH.
Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors.
J Clin Oncol. 23: 1885-93, 2005. [Journal]
45)  Xu W, Yuan X, Xiang Z, Mimnaugh E, Marcu M, Neckers L.
Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complex.
Nat Struct Mol Biol. 12: 120-6, 2005. [Journal]
46)  Fumo G, Akin C, Metcalfe DD, Neckers L.
17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells.
Blood. 103: 1078-84, 2004. [Journal]
47)  Akin C, Fumo G, Yavuz AS, Lipsky PE, Neckers L, Metcalfe DD.
A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib.
Blood. 103: 3222-5, 2004. [Journal]
48)  Isaacs JS, Jung YJ, Neckers L.
ARNT promotes oxygen-independent stabilization of hypoxia inducible factor-1 a by modulating an Hsp90-dependent regulatory pathway.
J Biol Chem. 2004. [Journal]
49)  Nielsen TO, Andrews HN, Cheang M, Kucab JE, Hsu FD, Ragaz J, Gilks CB, Makretsov N, Bajdik CD, Brookes C, Neckers LM, Evdokimova V, Huntsman DG, Dunn SE.
Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: potential for intervention with 17-allylamino geldanamycin.
Cancer Res. 64: 286-91, 2004. [Journal]
50)  Eustace BK, Sakurai T, Stewart JK, Yimlamai D, Unger C, Zehetmeier C, Lain B, Torella C, Henning SW, Beste G, Scroggins BT, Neckers L, Ilag LL, Jay DG.
Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness.
Nat Cell Biol. 6: 507-14, 2004. [Journal]
51)  Lee YS, Marcu MG, Neckers L.
Quantum chemical calculations and mutational analysis suggest heat shock protein 90 catalyzes trans-cis isomerization of geldanamycin.
Chem Biol. 11: 991-8, 2004. [Journal]
52)  Mimnaugh EG, Xu W, Vos M, Yuan X, Isaacs JS, Bisht KS, Gius D, Neckers L.
Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity.
Mol Cancer Ther. 3: 551-66, 2004. [Journal]
53)  Neckers L, Lee YS.
Cancer: the rules of attraction.
Nature. 425: 357-9, 2003. [Journal]
54)  Dai Q, Zhang C, Wu Y, McDonough H, Whaley RA, Godfrey V, Li HH, Madamanchi N, Xu W, Neckers L, Cyr D, Patterson C.
CHIP activates HSF1 and confers protection against apoptosis and cellular stress.
EMBO J. 22: 5446-58, 2003. [Journal]
55)  Neckers L.
Development of small molecule Hsp90 inhibitors: utilizing both forward and reverse chemical genomics for drug identification.
Curr Med Chem. 10: 733-9, 2003. [Journal]
56)  Neckers L.
Development of small molecule Hsp90 inhibitors: utilizing both forward and reverse chemical genomics for drug identification.
Curr Med Chem. 10: 733-9, 2003. [Journal]
57)  Bisht KS, Bradbury CM, Mattson D, Kaushal A, Sowers A, Markovina S, Ortiz KL, Sieck LK, Isaacs JS, Brechbiel MW, Mitchell JB, Neckers LM, Gius D.
Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity.
Cancer Res. 63: 8984-95, 2003. [Journal]
58)  Isaacs JS, Xu W, Neckers L.
Heat shock protein 90 as a molecular target for cancer therapeutics.
Cancer Cell. 3: 213-7, 2003. [Journal]
59)  Jung YJ, Isaacs JS, Lee S, Trepel J, Neckers L.
IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis.
FASEB J. 17: 2115-7, 2003. [Journal]
60)  Marcu MG, Neckers LM.
The C-terminal half of heat shock protein 90 represents a second site for pharmacologic intervention in chaperone function.
Curr Cancer Drug Targets. 3: 343-7, 2003. [Journal]
61)  Xu W, Yuan X, Jung YJ, Yang Y, Basso A, Rosen N, Chung EJ, Trepel J, Neckers L.
The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells.
Cancer Res. 63: 7777-84, 2003. [Journal]
62)  Xu W, Marcu M, Yuan X, Mimnaugh E, Patterson C, Neckers L.
Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu.
Proc Natl Acad Sci U S A. 99: 12847-52, 2002. [Journal]
63)  Citri A, Alroy I, Lavi S, Rubin C, Xu W, Grammatikakis N, Patterson C, Neckers L, Fry DW, Yarden Y.
Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy.
EMBO J. 21: 2407-17, 2002. [Journal]
64)  Neckers L.
Heat shock protein 90 inhibition by 17-allylamino-17- demethoxygeldanamycin: a novel therapeutic approach for treating hormone-refractory prostate cancer.
Clin Cancer Res. 8: 962-6, 2002. [Journal]
65)  Marcu MG, Doyle M, Bertolotti A, Ron D, Hendershot L, Neckers L.
Heat shock protein 90 modulates the unfolded protein response by stabilizing IRE1alpha.
Mol Cell Biol. 22: 8506-13, 2002. [Journal]
66)  Marcu MG, Doyle M, Bertolotti A, Ron D, Hendershot L, Neckers L.
Heat shock protein 90 modulates the unfolded protein response by stabilizing IRE1alpha.
Mol Cell Biol. 22: 8506-13, 2002. [Journal]
67)  Neckers L.
Hsp90 Inhibitors as Novel Cancer Chemotherapeutic Agents.
Expert Opinion in Emerging Drugs. 277-288, 2002. [Journal]
68)  Neckers L.
Hsp90 inhibitors as novel cancer chemotherapeutic agents.
Trends Mol Med. 8: S55-61, 2002. [Journal]
69)  Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F, Neckers LM.
Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway.
J Biol Chem. 277: 29936-44, 2002. [Journal]
70)  Xu W, Mimnaugh EG, Kim JS, Trepel JB, Neckers LM.
Hsp90, not Grp94, regulates the intracellular trafficking and stability of nascent ErbB2.
Cell Stress Chaperones. 7: 91-6, 2002. [Journal]
71)  Mimnaugh EG, Neckers LM.
Immunoblotting methods for the study of protein ubiquitination.
Methods Mol Biol. 194: 179-203, 2002. [Journal]
72)  Jung YJ, Isaacs JS, Lee S, Trepel J, Liu ZG, Neckers L.
Microtubule disruption utilizes a NFkB-dependent pathway to upregulate HIF-1alpha protein.
J. Biol. Chem. In Press, 2002. [Journal]
73)  Yu X, Guo ZS, Marcu MG, Neckers L, Nguyen DM, Chen GA, Schrump DS.
Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228.
J Natl Cancer Inst. 94: 504-13, 2002. [Journal]
74)  Bonvini P, Trepel JB, Neckers LM.
beta-catenin: A potential target for cancer chemotherapy, in Targets for Cancer Chemotherapy: Transcription Factors and Other Nuclear Proteins.
Humana Press, Inc., Totawa, NJ. L. Bandara & N. LaThangue, eds.: 71-100, 2001. [Journal]
75)  Mimnaugh EG, Kayastha G, McGovern NB, Hwang SG, Marcu MG, Trepel J, Cai SY, Marchesi VT, Neckers L.
Caspase-dependent deubiquitination of monoubiquitinated nucleosomal histone H2A induced by diverse apoptogenic stimuli.
Cell Death Differ. 8: 1182-96, 2001. [Journal]
76)  Yunmbam MK, Li QQ, Mimnaugh EG, Kayastha GL, Yu JJ, Jones LN, Neckers L, Reed E.
Effect of the proteasome inhibitor ALLnL on cisplatin sensitivity in human ovarian tumor cells.
Int J Oncol. 19: 741-8, 2001. [Journal]
77)  Bonvini P, An WG, Rosolen A, Nguyen P, Trepel J, Garcia de Herreros A, Dunach M, Neckers LM.
Geldanamycin abrogates ErbB2 association with proteasome-resistant beta-catenin in melanoma cells, increases beta-catenin-E-cadherin association, and decreases beta-catenin-sensitive transcription.
Cancer Res. 61: 1671-7, 2001. [Journal]
78)  Li QQ, Yunmbam MK, Zhong X, Yu JJ, Mimnaugh EG, Neckers L, Reed E.
Lactacystin enhances cisplatin sensitivity in resistant human ovarian cancer cell lines via inhibition of DNA repair and ERCC-1 expression.
Cell Mol Biol (Noisy-le-grand). 47 Online Pub: OL61-72, 2001. [Journal]
79)  Agnew EB, Wilson RH, Grem JL, Neckers L, Bi D, Takimoto CH.
Measurement of the novel antitumor agent 17-(allylamino)-17-demethoxygeldanamycin in human plasma by high-performance liquid chromatography.
J Chromatogr B Biomed Sci Appl. 755: 237-43, 2001. [Journal]
80)  Casibang M, Purdom S, Jakowlew S, Neckers L, Zia F, Ben-Av P, Hla T, You L, Jablons DM, Moody TW.
Prostaglandin E2 and vasoactive intestinal peptide increase vascular endothelial cell growth factor mRNAs in lung cancer cells.
Lung Cancer. 31: 203-12, 2001. [Journal]
81)  Isaacs JS, Saito S, Neckers LM.
Requirement for HDM2 activity in the rapid degradation of p53 in neuroblastoma.
J Biol Chem. 276: 18497-506, 2001. [Journal]
82)  Xu W, Mimnaugh E, Rosser MF, Nicchitta C, Marcu M, Yarden Y, Neckers L.
Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90.
J Biol Chem. 276: 3702-8, 2001. [Journal]
83)  Soga S, Sharma SV, Shiotsu Y, Shimizu M, Tahara H, Yamaguchi K, Ikuina Y, Murakata C, Tamaoki T, Kurebayashi J, Schulte TW, Neckers LM, Akinaga S.
Stereospecific antitumor activity of radicicol oxime derivatives.
Cancer Chemother Pharmacol. 48: 435-45, 2001. [Journal]
84)  Blagosklonny MV, Fojo T, Bhalla KN, Kim JS, Trepel JB, Figg WD, Rivera Y, Neckers LM.
The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy.
Leukemia. 15: 1537-43, 2001. [Journal]
85)  Neckers LM.
Can the heat shock protein 90 inhibitor geldanamycin be designed to specifically inhibit HER-2 tyrosine kinase.
Drug Resist Updat. 3: 203-205, 2000. [Journal]
86)  Lewis J, Devin A, Miller A, Lin Y, Rodriguez Y, Neckers L, Liu ZG.
Disruption of hsp90 function results in degradation of the death domain kinase, receptor-interacting protein (RIP), and blockage of tumor necrosis factor-induced nuclear factor-kappaB activation.
J Biol Chem. 275: 10519-26, 2000. [Journal]
87)  Garayoa M, Martínez A, Lee S, Pío R, An WG, Neckers L, Trepel J, Montuenga LM, Ryan H, Johnson R, Gassmann M, Cuttitta F.
Hypoxia-inducible factor-1 (HIF-1) up-regulates adrenomedullin expression in human tumor cell lines during oxygen deprivation: a possible promotion mechanism of carcinogenesis.
Mol Endocrinol. 14: 848-62, 2000. [Journal]
88)  Shiotsu Y, Neckers LM, Wortman I, An WG, Schulte TW, Soga S, Murakata C, Tamaoki T, Akinaga S.
Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G(1) phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex.
Blood. 96: 2284-91, 2000. [Journal]
89)  Bonvini P, Hwang SG, El-Gamil M, Robbins P, Kim JS, Trepel J, Neckers L.
Nuclear beta-catenin displays GSK-3beta- and APC-independent proteasome sensitivity in melanoma cells.
Biochim Biophys Acta. 1495: 308-18, 2000. [Journal]
90)  Mimnaugh EG, Yunmbam MK, Li Q, Bonvini P, Hwang SG, Trepel J, Reed E, Neckers L.
Prevention of cisplatin-DNA adduct repair and potentiation of cisplatin-induced apoptosis in ovarian carcinoma cells by proteasome inhibitors.
Biochem Pharmacol. 60: 1343-54, 2000. [Journal]
91)  An WG, Schulte TW, Neckers LM.
The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome.
Cell Growth Differ. 11: 355-60, 2000. [Journal]
92)  Marcu MG, Chadli A, Bouhouche I, Catelli M, Neckers LM.
The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone.
J Biol Chem. 275: 37181-6, 2000. [Journal]

This page was last updated on 11/24/2008.